Camlin Fine Sciences

₹101 2.3 | 2.3%

WEBSITE BSE:532834 NSE : CAMLINFINE 10 May, 16:01

Market Cap ₹1691 Cr.

Stock P/E -289.7

P/B 2

Current Price ₹101

Book Value ₹ 51.6

Face Value 1

52W High ₹186.3

Dividend Yield 0%

52W Low ₹ 88.5

Edit Ratio

Camlin Fine Sciences Research see more...

Camlin Fine Sciences - Well-positioned to benefit from Sectoral Tailwinds

Overview Inc. Year: 1993Industry: Chemicals

Camlin Fine Sciences Ltd is engaged in fine chemicals enterprise. It is a company of antioxidants and shelf life extensions, aroma ingredients, performance chemical products and associated solutions for food, animal vitamins, pet meals, pharmaceutical and petrochemical industries internationally. Its products include BHA and TBHQ. The Company's services in shelf life solutions comprises XTENDRA, NASURE, REDOX, ENERSUPRA, RENDEROX, POLIACID and BIACID. It produces Catechol, the element used to make Vanillin and Ethyl-Vanillin, this is utilized in a variety of packages, including bakery products, confectioneries, dietary supplements, milk, sweets, chocolates, custard powder, masala incense stick, scented incense stick, pharma syrups, animal nutrients, chew tabs and laboratory chemicals. Its performance chemical compounds commercial enterprise is involved in supplying distinctiveness chemicals, inclusive of Guaiacol, Veratrole, TBC, MEHQ, ODEB, CME, 4-MAP, Hydroquinone and Catechol.

Camlin Fine Sciences Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Camlin Fine Sciences Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	311	381	389	384	483	388	427	420	406	386
Other Income	1	6	21	1	3	10	2	6	2	2
Total Income	312	386	411	385	486	398	429	426	408	388
Total Expenditure	289	326	365	337	436	338	383	381	385	363
Operating Profit	23	61	46	48	50	60	46	45	22	25
Interest	9	7	10	19	10	12	10	10	15	14
Depreciation	13	13	16	14	14	16	18	19	19	21
Exceptional Income / Expenses	0	0	0	0	0	0	-10	0	0	0
Profit Before Tax	1	41	20	15	26	32	8	16	-12	-10
Provision for Tax	5	14	7	11	16	9	5	4	9	5
Profit After Tax	-4	27	13	4	10	23	3	12	-21	-14
Adjustments	-2	2	2	2	3	1	6	4	1	2
Profit After Adjustments	-6	29	15	6	13	24	9	16	-19	-12
Adjusted Earnings Per Share	-0.4	2.3	1	0.4	0.8	1.5	0.6	0.9	-1.2	-0.7

Camlin Fine Sciences Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	374	509	558	489	534	721	892	1049	1187	1412	1682	1639
Other Income	11	12	8	4	16	13	14	3	11	37	6	12
Total Income	385	521	567	494	550	734	906	1053	1198	1449	1688	1651
Total Expenditure	328	449	474	398	503	706	819	914	1000	1258	1471	1512
Operating Profit	57	71	93	96	46	28	87	139	198	191	217	138
Interest	20	25	24	24	31	32	41	48	48	41	64	49
Depreciation	14	12	16	17	22	27	29	33	44	56	63	77
Exceptional Income / Expenses	0	0	0	-5	0	0	0	0	0	0	-10	-10
Profit Before Tax	24	35	53	50	-6	-31	17	58	105	94	80	2
Provision for Tax	8	6	-2	14	-2	-7	14	28	40	34	41	23
Profit After Tax	15	29	55	36	-4	-24	3	30	65	60	40	-20
Adjustments	-0	-0	-0	0	-7	-6	-2	0	-14	0	12	13
Profit After Adjustments	15	29	55	36	-11	-30	1	30	51	61	52	-6
Adjusted Earnings Per Share	1.6	3	5.7	3.7	-1.1	-2.4	0	2.5	4	3.9	3.3	-0.4

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	19%	17%	18%	16%
Operating Profit CAGR	14%	16%	51%	14%
PAT CAGR	-33%	10%	0%	10%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-40%	-17%	19%	15%
ROE Average	6%	10%	8%	15%
ROCE Average	10%	12%	11%	15%

Camlin Fine Sciences Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	65	93	135	176	213	371	371	403	643	748	819
Minority's Interest	0	0	0	0	18	62	59	57	70	17	5
Borrowings	38	29	28	21	51	110	194	212	273	388	408
Other Non-Current Liabilities	3	-3	-11	-10	-19	-38	-39	-26	-15	16	5
Total Current Liabilities	263	246	262	280	386	471	460	548	478	595	793
Total Liabilities	369	365	413	468	648	977	1046	1193	1449	1764	2030
Fixed Assets	83	83	106	140	199	276	270	304	581	601	858
Other Non-Current Assets	3	25	8	28	30	35	103	215	72	269	85
Total Current Assets	283	257	299	300	419	666	672	675	795	891	1086
Total Assets	369	365	413	468	648	977	1046	1193	1449	1764	2030

Camlin Fine Sciences Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	10	16	4	9	8	21	38	53	52	76	108
Cash Flow from Operating Activities	56	27	46	72	-9	-15	-9	86	117	145	51
Cash Flow from Investing Activities	-19	-32	-26	-66	-83	-149	-2	-90	-133	-249	-125
Cash Flow from Financing Activities	-21	-6	-15	-7	91	182	26	3	39	136	60
Net Cash Inflow / Outflow	16	-12	4	-1	-1	18	15	-1	23	32	-14
Closing Cash & Cash Equivalent	26	4	9	8	21	38	53	52	76	108	94

Camlin Fine Sciences Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	1.61	3.04	5.74	3.71	-1.08	-2.45	0.05	2.5	4	3.87	3.32
CEPS(Rs)	3.06	4.29	7.43	5.47	1.67	0.22	2.64	5.17	8.6	7.41	6.51
DPS(Rs)	0.3	0.35	0.45	0.45	0	0	0	0	0	0	0
Book NAV/Share(Rs)	6.95	9.86	14.06	18.23	20.34	28.77	28.74	33.21	38.57	41.61	47.18
Core EBITDA Margin(%)	12.03	11.5	14.75	18.2	5.61	2.03	8.17	12.89	15.73	10.92	12.51
EBIT Margin(%)	11.39	11.51	13.44	14.77	4.49	0.15	6.46	10.09	12.91	9.54	8.6
Pre Tax Margin(%)	6.14	6.74	9.26	9.92	-1.1	-4.25	1.87	5.55	8.85	6.66	4.78
PAT Margin (%)	3.95	5.56	9.65	7.1	-0.81	-3.32	0.34	2.84	5.51	4.28	2.37
Cash Profit Margin (%)	7.51	7.84	12.49	10.49	3.18	0.37	3.59	5.97	9.24	8.24	6.08
ROA(%)	4.62	7.83	14.15	8.13	-0.8	-2.95	0.3	2.66	4.95	3.76	2.1
ROE(%)	25.61	36.29	48.31	23.04	-2.29	-8.57	0.86	7.94	14.61	10.55	5.71
ROCE(%)	23.65	27.41	28.5	22.86	5.46	0.17	7.32	12.02	15.25	11.37	10.24
Receivable days	84.48	66.48	68.69	68.37	73.54	88.44	84.82	80.39	80.48	73.72	65.58
Inventory Days	111.24	91.12	78.55	112.09	123.85	110.3	107.28	101.51	95.03	89.29	101.91
Payable days	271.23	170.42	139.37	181.39	121.7	110.68	131.61	115.68	103.88	94.24	117.17
PER(x)	4.8	6.29	15.39	23.88	0	0	1047.27	15.76	34.97	36.09	38.39
Price/Book(x)	1.11	1.94	6.28	4.85	4.4	3.54	1.73	1.19	3.62	3.35	2.7
Dividend Yield(%)	3.88	1.83	0.51	0.51	0	0	0	0	0	0	0
EV/Net Sales(x)	0.46	0.62	1.77	2.08	2.3	2.16	1.08	0.89	1.84	1.89	1.59
EV/Core EBITDA(x)	3.01	4.41	10.67	10.59	26.47	56.61	11.1	6.77	11.05	13.99	12.37
Net Sales Growth(%)	11.45	36.15	9.75	-12.35	9.11	34.96	23.81	17.6	13.15	18.95	19.08
EBIT Growth(%)	58.57	36.47	28.79	-2.87	-67.01	-95.62	6271.24	83.61	44.79	-12.05	7.26
PAT Growth(%)	290.21	90.02	91.53	-34.92	-112.39	-440.01	112.45	892.44	119.1	-7.63	-34.06
EPS Growth(%)	296.72	89.15	88.69	-35.42	-129.08	-126.93	101.95	5152.94	59.86	-3.3	-14.19
Debt/Equity(x)	1.93	1.61	1.19	1.02	1.57	1.07	1.32	1.31	1.09	0.95	1.05
Current Ratio(x)	1.08	1.04	1.14	1.07	1.09	1.41	1.46	1.23	1.66	1.5	1.37
Quick Ratio(x)	0.51	0.6	0.62	0.45	0.57	0.91	0.84	0.69	0.99	0.87	0.65
Interest Cover(x)	2.17	2.41	3.22	3.05	0.8	0.03	1.41	2.22	3.18	3.3	2.25
Total Debt/Mcap(x)	1.73	0.83	0.19	0.21	0.36	0.3	0.76	1.1	0.3	0.28	0.39

Camlin Fine Sciences Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	21.6	17.56	17.56	17.55	17.55	17.55	16.52	48.03	48.03	48.03
FII	4.81	10.5	10.74	11.32	10.94	10.18	10.12	1.61	0.99	1.69
DII	17.88	14.47	14.2	13.53	12.54	12.36	9.34	3.9	3.75	4.54
Public	55.7	57.46	57.51	57.6	58.97	59.91	64.02	46.46	47.23	45.74
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	2.76	2.76	2.76	2.76	2.76	2.76	2.76	8.04	8.04	8.04
FII	0.61	1.65	1.69	1.78	1.72	1.6	1.69	0.27	0.17	0.28
DII	2.28	2.27	2.23	2.12	1.97	1.94	1.56	0.65	0.63	0.76
Public	7.11	9.02	9.03	9.05	9.26	9.41	10.71	7.78	7.91	7.66
Others	0	0	0	0	0	0	0	0	0	0
Total	12.76	15.7	15.7	15.71	15.71	15.71	16.74	16.75	16.75	16.75

Pros

Cons

Promoter holding is low: 48.03%.
Company has a low return on equity of 10% over the last 3 years.
Debtor days have increased from 94.24 to 117.17days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.